Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure

International Journal of Molecular Medicine

Volumn 26, Issue 1, 2010, Pages 159-164

  Yang, Dachun ^a   Ma, Shuangtao ^a   Tan, Yan ^a   Li, De ^a   Tang, Bing ^a   Zhang, Xin ^a   Sun, Meiqin ^a   Yang, Yongjian ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Calcineurin; Calpain; Congestive heart failure

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CAIN PROTEIN; CALCINEURIN; CALPAIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEART MUSCLE; HUMAN; HUMAN TISSUE; MALE; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TISSUE REGENERATION;

EID: 77954742071     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000448     Document Type: Article

References (25)

1. Demirovic J, Prineas R and Rudolph M: Epidemiology of congestive heart failure in three ethnic groups. Congest Heart Fail 7: 93-96, 2001. (Pubitemid 32927267)
2. Takano H, Hasegawa H, Nagai T and Komuro I: Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med 42: 465-469, 2003. (Pubitemid 36926806)
3. Mehta PK and Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97, 2007.
4. Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP and Baud L: Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 102: 720-728, 2008.
5. Yang D, Ma S, Li D, Tang B and Yang Y: Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem Biophys Res Commun 388: 606-611, 2009.
6. Croall DE and DeMartino GN: Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev 71: 813-847, 1991.
7. Goll DE, Thompson VF, Li H, Wei W and Cong J: The calpain system. Physiol Rev 83: 731-801, 2003.
8. Heidrich FM and Ehrlich BE: Calcium, calpains, and cardiac hypertrophy: a new link. Circ Res 104: e19-e20, 2009.
9. Saido TC, Sorimachi H and Suzuki K: Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8: 814-822, 1994. (Pubitemid 24979531)
10. Kim MJ, Jo DG, Hong GS, Kim BJ, Lai M, Cho DH, Kim KW, Bandyopadhyay A, Hong YM, Kim DH, Cho C, Liu JO, Snyder SH and Jung YK: Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death. Proc Natl Acad Sci USA 99: 9870-9875, 2002.
11. Lai MM, Burnett PE, Wolosker H, Blackshaw S and Snyder SH: Cain, a novel physiologic protein inhibitor of calcineurin. J Biol Chem 273: 18325-18331, 1998.
12. Sun L, Youn HD, Loh C, Stolow M, He W and Liu JO: Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 8: 703-711, 1998.
13. Lai MM, Luo HR, Burnett PE, Hong JJ and Snyder SH: The calcineurin-binding protein cain is a negative regulator of synaptic vesicle endocytosis. J Biol Chem 275: 34017-34020, 2000.
14. Lim HW and Molkentin JD: Calcineurin and human heart failure. Nat Med 5: 246-247, 1999.
15. Naik GO, Moe GW and Armstrong PW: Specific and nonspecific measurements of tissue angiotensin II cascade members. J Pharm Biomed Anal 24: 947-955, 2001.
16. Van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH and Voors AA: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106: 367-372, 2006.
17. Pilop C, Aregger F, Gorman RC, Brunisholz R, Gerrits B, Schaffner T, Gorman JH III, Matyas G, Carrel T and Frey BM: Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 120: 983-991, 2009.
18. Li Y, Feng Q, Arnold M and Peng T: Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 84: 100-110, 2009.
19. Yoshikawa Y, Hagihara H, Ohga Y, Nakajima-Takenaka C, Murata KY, Taniguchi S and Takaki M: Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics. Am J Physiol Heart Circ Physiol 288: H1690-H1698, 2005.
20. Khalil PN, Neuhof C, Huss R, Pollhammer M, Khalil MN, Neuhof H, Fritz H and Siebeck M: Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol 528: 124-131, 2005.
21. Maekawa A, Lee JK, Nagaya T, Kamiya K, Yasui K, Horiba M, Miwa K, Uzzaman M, Maki M, Ueda Y and Kodama I: Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion. J Mol Cell Cardiol 35: 1277-1284, 2003.
22. Williams RS: Calcineurin signaling in human cardiac hypertrophy. Circulation 105: 2242-2243, 2002.
23. Ritter O, Hack S, Schuh K, Rothlein N, Perrot A, Osterziel KJ, Schulte HD and Neyses L: Calcineurin in human heart hypertrophy. Circulation 105: 2265-2269, 2002.
24. Wilkins BJ and Molkentin JD: Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 541: 1-8, 2002.
25. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y and Komuro I: Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104: 97-101, 2001. (Pubitemid 32623296)